meta:
  schema_version: '1.0'
  compatible_engine: cellswarm>=2.0
  calibrated_from: GSE169246 (Zhang et al. 2021)
  calibration_date: '2026-02-13'
drug_id: atezolizumab
generic_name: Atezolizumab
brand_name: Tecentriq
drug_class: immune_checkpoint_inhibitor
subclass: anti_PDL1
molecular_type: monoclonal_antibody
fda_status: approved
approved_indications:
- TNBC
- NSCLC
targets:
- name: PD-L1
  gene: CD274
  type: ligand
  action: antagonist
  selectivity: high
cell_effects:
  CD8_T:
    direct: true
    state_effects:
    - parameter: exhaustion
      direction: decrease
      rate_per_step: 0.07
    - parameter: activation
      direction: increase
      rate_per_step: 0.05
    - parameter: cytotoxicity
      direction: increase
      rate_per_step: 0.04
    functional_effects:
    - action: attack
      probability_modifier: 0.18
    - action: proliferate
      probability_modifier: 0.08
    data_calibration:
      source: GSE169246
      proportion_change: -0.00069
      fold_change: 0.9677
      direction: decrease
  Tumor:
    direct: true
    state_effects:
    - parameter: immune_evasion
      direction: decrease
      rate_per_step: 0.05
    notes: Blocks PD-L1 on tumor surface directly
    data_calibration:
      source: GSE169246
      proportion_change: 0.00018
      fold_change: 1.1651
      direction: increase
  Treg:
    direct: false
    state_effects: []
    data_calibration:
      source: GSE169246
      proportion_change: -0.00082
      fold_change: 0.87
      direction: decrease
  Macrophage:
    direct: false
    state_effects:
    - parameter: polarization
      direction: decrease
      rate_per_step: 0.02
    data_calibration:
      source: GSE169246
      proportion_change: -0.00107
      fold_change: 0.9269
      direction: decrease
  NK:
    direct: false
    state_effects:
    - parameter: activation
      direction: increase
      rate_per_step: 0.02
    data_calibration:
      source: GSE169246
      proportion_change: 0.00933
      fold_change: 1.2805
      direction: increase
  B_cell:
    direct: false
    state_effects: []
    data_calibration:
      source: GSE169246
      proportion_change: -0.00694
      fold_change: 0.7024
      direction: decrease
environment_effects:
- field: PD_L1
  action: neutralize
  magnitude: 0.9
- field: IFN_gamma
  action: amplify
  magnitude: 0.08
  onset: delayed
  delay_steps: 2
pharmacokinetics:
  administration: IV
  standard_dose: 1200 mg q3w
  onset_steps: 1
  peak_steps: 3
  half_life_steps: 27
  concentration_curve: plateau
  steady_state_fraction: 0.85
dose_response:
  model: hill
  ec50: 0.5
  hill_coefficient: 2.0
  max_effect: 1.0
cancer_specific_modifiers:
  TNBC:
    efficacy_modifier: 0.75
    notes: IMpassion130 PD-L1+ IC>=1%
  Melanoma:
    efficacy_modifier: 0.7
    notes: Not first-line
  NSCLC:
    efficacy_modifier: 0.85
    notes: IMpower150
  CRC-MSI-H:
    efficacy_modifier: 0.6
    notes: Limited data
  CRC-MSS:
    efficacy_modifier: 0.1
    notes: Ineffective
  Ovarian:
    efficacy_modifier: 0.3
    notes: Limited efficacy
resistance:
- mechanism: Alternative checkpoint upregulation (TIGIT, LAG-3)
  onset_steps: 20
  probability: 0.1
- mechanism: TGF-beta mediated T cell exclusion
  onset_steps: 15
  probability: 0.08
references:
- description: 'IMpassion130: Atezo+nab-paclitaxel in TNBC. Schmid et al. NEJM 2018'
  pmid: '30345906'
  verified: true
